Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. This evidence concerns the gene IGFBP3 and gastrointestinal stromal tumor.